WO2014009970A3 - Linagliptin solid dispersion - Google Patents
Linagliptin solid dispersion Download PDFInfo
- Publication number
- WO2014009970A3 WO2014009970A3 PCT/IN2013/000417 IN2013000417W WO2014009970A3 WO 2014009970 A3 WO2014009970 A3 WO 2014009970A3 IN 2013000417 W IN2013000417 W IN 2013000417W WO 2014009970 A3 WO2014009970 A3 WO 2014009970A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- linagliptin
- solid dispersion
- preparation
- pharmaceutically acceptable
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Abstract
The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/589,495 US9381199B2 (en) | 2012-07-09 | 2013-07-08 | Linagliptin solid dispersion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
INCH27802012 | 2012-07-09 | ||
ININ2780/CHE/2012 | 2012-07-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014009970A2 WO2014009970A2 (en) | 2014-01-16 |
WO2014009970A3 true WO2014009970A3 (en) | 2015-07-30 |
Family
ID=49916619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2013/000417 WO2014009970A2 (en) | 2012-07-09 | 2013-07-08 | Linagliptin solid dispersion |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014009970A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9381199B2 (en) | 2012-07-09 | 2016-07-05 | Hetero Research Foundation | Linagliptin solid dispersion |
WO2016207364A1 (en) * | 2015-06-25 | 2016-12-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of a xanthine-based compound |
EP3452759B1 (en) * | 2016-05-03 | 2021-03-17 | Carrier Corporation | Cooling and/or heating system with vane-axial fan |
CN112961155A (en) * | 2021-03-16 | 2021-06-15 | 华北水利水电大学 | Preparation method of linagliptin |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
US7407955B2 (en) * | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20100209506A1 (en) * | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US20110263617A1 (en) * | 2008-09-10 | 2011-10-27 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20120046224A1 (en) * | 2009-03-12 | 2012-02-23 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
-
2013
- 2013-07-08 WO PCT/IN2013/000417 patent/WO2014009970A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
US7407955B2 (en) * | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20110263617A1 (en) * | 2008-09-10 | 2011-10-27 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20100209506A1 (en) * | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US20120046224A1 (en) * | 2009-03-12 | 2012-02-23 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
Also Published As
Publication number | Publication date |
---|---|
WO2014009970A2 (en) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279304A (en) | Cytotoxic benzodiazepine derivatives, compositions comprising the same and uses thereof | |
IL269858A (en) | Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof | |
IL239639A0 (en) | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor | |
IL233154A (en) | Compounds, pharmaceutical compositions comprising the same and uses thereof | |
IL221952A (en) | 2,3-dihydro-1h-inden-1-yl-2,7- diazaspiro[3.5] nonane derivatives and pharmaceutical compositions comprising the same | |
WO2013150495A3 (en) | Preparation of ticagrelor | |
WO2014076712A3 (en) | Lurasidone hydrochloride solid dispersion | |
WO2011130615A3 (en) | Preparation of lacosamide | |
WO2012068441A3 (en) | Intedanib salts and solid state forms thereof | |
WO2015104658A3 (en) | Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin | |
MX359288B (en) | Ivabradine hydrochloride form iv. | |
ZA201301463B (en) | Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same | |
WO2013164839A8 (en) | Amorphous form of apixaban, process of preparation and compositions thereof | |
HK1162262A1 (en) | Base, products containing the same, preparation methods and uses thereof | |
WO2012085927A3 (en) | Tadalafil compositions | |
IN2012DN02793A (en) | ||
IL212942A (en) | Rifamycin derivatives, process for their preparation, pharmaceutical compositions comprising the same and uses thereof | |
HK1204615A1 (en) | (1r,4r)7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof (1r4r)7--2-[222]-5- | |
WO2014009970A3 (en) | Linagliptin solid dispersion | |
IL225440A (en) | Cyclohexane derivatives, compositions comprising the same and uses thereof | |
WO2014105777A8 (en) | Cobicostat dichlohydrate salt | |
WO2013150544A3 (en) | Ivabradine hydrochloride solid dispersion | |
WO2014115169A3 (en) | Crizotinib solid dispersion | |
WO2015044434A3 (en) | Fluor-9-methyl-β-carbolines | |
AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13816209 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14589495 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13816209 Country of ref document: EP Kind code of ref document: A2 |